European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: Summary of the 2011 4th European Conference on Infections in Leukemia

Haematologica

Volumn 98, Issue 12, 2013, Pages 1826-1835

  Averbuch, Diana ^a   Orasch, Christina ^b   Cordonnier, Catherine ^c   Livermore, David M ^d   Mikulska, Małgorzata ^e   Viscoli, Claudio ^e   Gyssens, Inge C ^f,g,h   Kern, Winfried V ⁱ   Klyasova, Galina ^j   Marchetti, Oscar ^b   Engelhard, Dan ^a   Akova, Murat ^k  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^e UNIVERSITY OF GENOA   (Italy)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^h HASSELT UNIVERSITY   (Belgium)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

^j NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^k HACETTEPE UNIVERSITY   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFIXIME PLUS CLOXACILLIN; CEFTAZIDIME; CEPHALOSPORIN; COLISTIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; DISEASE COURSE; DRUG DOSE ESCALATION; EVIDENCE BASED PRACTICE; FEBRILE NEUTROPENIA; HEALTH CARE ORGANIZATION; HUMAN; INFECTION CONTROL; LEUKEMIA; NONHUMAN; PATHOGENESIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; EUROPE; FEVER; HUMANS; LEUKEMIA; NEUTROPENIA; PRACTICE GUIDELINES AS TOPIC;

EID: 84889824250     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.091025     Document Type: Article

References (89)

1. Almyroudis NG, Fuller A, Jakubowski A, Sepkowitz K, Jaffe D, Small TN, et al. Preand post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2005;7(1):117.
2. Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis. 2001;33(7):947-53.
3. Mikulska M, Del Bono V, Raiola AM, Bruno B, Gualandi F, Occhini D, et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant. 2009;15(1):47-53.
4. Ninin E, Milpied N, Moreau P, AndreRichet B, Morineau N, Mahe B, et al. Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. Clin Infect Dis. 2001; 33(1):41-7.
5. Poutsiaka DD, Price LL, Ucuzian A, Chan GW, Miller KB, Snydman DR. Blood stream infection after hematopoietic stem cell transpl antation is associated with increased mortality. Bone Marrow Transplant. 2007; 40(1):63-70.
6. Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P, et al. Incidence and clinical impact of extendedspectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect. 2009;58(4): 299-307.
7. Giamarellou H. Multidrug-resistant Gramnegative bacteria: how to treat and for how long. Int J Antimicrob Agents. 2010;36 (Suppl 2):S50-4.
8. Kamboj M, Chung D, Seo SK, Pamer EG, Sepkowitz KA, Jakubowski AA, et al. The changing epidemiology of vancomycinresistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant. 2010;16(11):1576-81.
9. Weinstock DM, Conlon M, Iovino C, Aubrey T, Gudiol C, Riedel E, et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2007;13(5):61521.
10. Averbuch D, Cordonnier C, Livermore DM, Mikulska M, Orasch C, Viscoli C, et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica. 2013;
11. Cordonnier C, Calandra T. The first European Conference on Infections in Leukemia: Why and How? Eur J Cancer. 2007;Supp 5:2-4.
12. Empirical and Targeted Antibiotics in Haematological Cancer Patients 2011 [3 january 2013]. Available from: http://www.ebmt.org/Contents/Resources/Library/ECIL/Documents/ECIL4%202011 %20Bacterial%20resistance%20in%20Haematology.pdf.
13. Empirical and targeted antibacterial therapy in neutropenic patients 2013 [30 April 2013]. European Conference on Infections in leukaemia (ECIL)]. Available from: http://www.kobe.fr/ecil/program2011.htm
14. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56-93.
15. Caselli D, Cesaro S, Ziino O, Zanazzo G, Manicone R, Livadiotti S, et al. Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica. 2010;95(9):1612-5.
16. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol. 2006;55(Pt 12):1619-29.
17. Johnson LE, D'Agata EM, Paterson DL, Clarke L, Qureshi ZA, Potoski BA, et al. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients. Transpl Infect Dis. 2009;11(3):227-34.
18. Oliveira AL, de Souza M, Carvalho-Dias VM, Ruiz MA, Silla L, Tanaka PY, et al. Epidemiology of bacteremia and factors associated with multi-drug-resistant gramnegative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2007;39(12):775-81.
19. Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R, et al. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother. 2010;65(2):333-41.
20. Gudiol C, Tubau F, Calatayud L, GarciaVidal C, Cisnal M, Sanchez-Ortega I, et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother. 2011;66 (3):z657-63.
21. Ortega M, Marco F, Soriano A, Almela M, Martinez JA, Munoz A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother. 2009; 63(3):568-74.
22. Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori E, Leone F, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother. 2006;50 (2):498-504.
23. Ariffin H, Navaratnam P, Mohamed M, Arasu A, Abdullah WA, Lee CL, et al. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. Int J Infect Dis. 2000;4(1):21-5.
24. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997;25(2):247-59.
25. Martinez JA, Cobos-Trigueros N, Soriano A, Almela M, Ortega M, Marco F, et al. Influence of empiric therapy with a betalactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother. 2010;54(9): 3590-6. 1833
26. Trecarichi EM, Tumbarello M, Caira M, Candoni A, Cattaneo C, Pastore D, et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica. 2011;96(1):e1-3; author reply e4.
27. Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect. 2013;19(1):E23-30.
28. Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother. 2008;52(4): 1413-8.
29. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29(12):1099-106.
30. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis. 2005; 191(4):588-95.
31. Dubberke ER, Hollands JM, Georgantopoulos P, Augustin K, DiPersio JF, Mundy LM, et al. Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? Bone Marrow Transplant. 2006;38(12):813-9.
32. Vergis EN, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Linden PK, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Ann Intern Med. 2001;135(7):484-92.
33. Avery R, Kalaycio M, Pohlman B, Sobecks R, Kuczkowski E, Andresen S, et al. Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant. 2005;35(5):497-9.
34. Kapur D, Dorsky D, Feingold JM, Bona RD, Edwards RL, Aslanzadeh J, et al. Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2000;25(2):147-52.
35. Zirakzadeh A, Gastineau DA, Mandrekar JN, Burke JP, Johnston PB, Patel R. Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2008;41(4):385-92.
36. Bossaer JB, Hall PD, Garrett-Mayer E. Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer. 2010;19(2):231-7.
37. Cohen ML, Murphy MT, Counts GW, Buckner CD, Clift RA, Meyers JD. Prediction by surveillance cultures of bacteremia among neutropenic patients treated in a protective environment. J Infect Dis. 1983;147(5):789-93.
38. Martinez JA, Aguilar J, Almela M, Marco F, Soriano A, Lopez F, et al. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-pro1834 ducing Escherichia coli or Klebsiella spp. in patients with bacteraemia. J Antimicrob Chemother. 2006;58(5):1082-5.
39. Narimatsu H, Kami M, Miyakoshi S, Yuji K, Matusmura T, Uchida N, et al. Value of pretransplant screening for colonization of Pseudomonas aeruginosa in reduced-intensity umbilical cord blood transplantation for adult patients. Ann Hematol. 2007; 86(6):449-51.
40. Ansari SR, Hanna H, Hachem R, Jiang Y, Rolston K, Raad I. Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. Cancer. 2007;109(12):2615-22.
41. Tancrede CH, Andremont AO. Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies. J Infect Dis. 1985;152(1):99103.
42. Tsiatis AC, Manes B, Calder C, Billheimer D, Wilkerson KS, Frangoul H. Incidence and clinical complications of vancomycinresistant enterococcus in pediatric stem cell transplant patients. Bone Marrow Transplant. 2004;33(9):937-41.
43. Wingard JR, Dick J, Charache P, Saral R. Antibiotic-resistant bacteria in surveillance stool cultures of patients with prolonged neutropenia. Antimicrob Agents Chemother. 1986;30(3):435-9.
44. Hyle EP, Bilker WB, Gasink LB, Lautenbach E. Impact of different methods for describing the extent of prior antibiotic exposure on the association between antibiotic use and antibiotic-resistant infection. Infect Control Hosp Epidemiol. 2007;28(6):647-54.
45. Kim SH, Kwon JC, Choi SM, Lee DG, Park SH, Choi JH, et al. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum betalactamase production and its impact on outcome. Ann Hematol. 2013;92(4):533-41.
46. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum betalactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32(8):1162-71.
47. Park SY, Kang CI, Joo EJ, Ha YE, Wi YM, Chung DR, et al. Risk factors for multidrug resistance in nosocomial bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist. 2012;18(5): 518-24.
48. Bow EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis. 2011;24(6):545-53.
49. Castagnola E, Haupt R, Micozzi A, Caviglia I, Testi AM, Giona F, et al. Differences in the proportions of fluoroquinolone-resistant Gram-negative bacteria isolated from bacteraemic children with cancer in two Italian centres. Clin Microbiol Infect. 2005;11(6):505-7.
50. Frère AT, Hermanne JP, Debouge MH, Fillet G, Beguin Y. Changing pattern of bacterial susceptibility to antibiotics in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2002;29(7):589-94.
51. Lopez-Dupla M, Martinez JA, Vidal F, Almela M, Soriano A, Marco F, et al. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates. Am J Infect Control. 2009;37(9):753-8.
52. Tumbarello M, Trecarichi EM, Bassetti M, De Rosa FG, Spanu T, Di Meco E, et al. Identifying patients harboring extendedspectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother. 2011;55(7):3485-90.
53. Garnica M, Maiolino A, Nucci M. Factors associated with bacteremia due to multidrug-resistant Gram-negative bacilli in hematopoietic stem cell transplant recipients. Braz J Med Biol Res. 2009;42(3):289-93.
54. Henning KJ, Delencastre H, Eagan J, Boone N, Brown A, Chung M, et al. Vancomycinresistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J. 1996;15(10):848-54.
55. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Salar A, Peris J, Granena A, et al. Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis. 1999;18(8):539-44.
56. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038-51.
57. Viscoli C, Bruzzi P, Castagnola E, Boni L, Calandra T, Gaya H, et al. Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer. 1994;30A(4):430-7.
58. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG, Levine AS, Deisseroth AB, et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med. 1979;67(2):194-200.
59. Link H, Maschmeyer G, Meyer P, Hiddemann W, Stille W, Helmerking M, et al. Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy. Ann Hematol. 1994;69(5): 231-43.
60. Santolaya ME, Villarroel M, Avendano LF, Cofre J. Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study. Clin Infect Dis. 1997;25(1):92-7.
61. Klaassen RJ, Allen U, Doyle JJ. Randomized placebo-controlled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia. J Pediatr Hematol Oncol. 2000;22(5):405-11.
62. Cherif H, Bjorkholm M, Engervall P, Johansson P, Ljungman P, Hast R, et al. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis. 2004;36 (8):593-600.
63. Aquino VM, Buchanan GR, Tkaczewski I, Mustafa MM. Safety of early hospital discharge of selected febrile children and adolescents with cancer with prolonged neutropenia. Med Pediatr Oncol. 1997;28(3): 191-5.
64. Aquino VM, Tkaczewski I, Buchanan GR. Early discharge of low-risk febrile neutropenic children and adolescents with cancer. Clin Infect Dis. 1997;25(1):74-8.
65. Bash RO, Katz JA, Cash JV, Buchanan GR. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer. 1994;74(1):189-96.
66. Cornelissen JJ, Rozenberg-Arska M, Dekker AW. Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin. Clin Infect Dis. 1995;21(5):1300-2.
67. Griffin TC, Buchanan GR. Hematologic predictors of bone marrow recovery in neutropenic patients hospitalized for fever: implications for discontinuation of antibiotics and early discharge from the hospital. J Pediatr. 1992;121(1):28-33.
68. Hodgson-Viden H, Grundy PE, Robinson JL. Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia. BMC Pediatr. 2005;5(1):10.
69. Lehrnbecher T, Stanescu A, Kuhl J. Short courses of intravenous empirical antibiotic treatment in selected febrile neutropenic children with cancer. Infection. 2002;30(1): 17-21.
70. Mullen CA, Buchanan GR. Early hospital discharge of children with cancer treated for fever and neutropenia: identification and management of the low-risk patient. J Clin Oncol. 1990;8(12):1998-2004.
71. Slobbe L, Waal L, Jongman LR, Lugtenburg PJ, Rijnders BJ. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study. Eur J Cancer. 2009;45(16):2810-7.
72. Horowitz HW, Holmgren D, Seiter K. Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies. Leuk Lymphoma. 1996;23(1-2):159-63.
73. Jones GR, Konsler GK, Dunaway RP, Gold SH, Cooper HA, Wells RJ. Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition. J Pediatr. 1994;124(5 Pt 1):703-8.
74. Joshi JH, Schimpff SC, Tenney JH, Newman KA, de Jongh CA. Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients? Am J Med. 1984;76(3):450-7.
75. Wacker P, Halperin DS, Wyss M, Humbert J. Early hospital discharge of children with fever and neutropenia: a prospective study. J Pediatr Hematol Oncol. 1997;19(3):208-11.
76. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, et al. Piperacillintazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother. 1995;39(2):445-52.
77. Cordonnier C, Herbrecht R, Pico JL, Gardembas M, Delmer A, Delain M, et al. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. Clin Infect Dis. 1997;24(1): 41-51.
78. Eggimann P, Glauser MP, Aoun M, Meunier F, Calandra T. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients. J Antimicrob Chemother. 1993;32 (Suppl B):151-63.
79. Giamarellou H, Bassaris HP, Petrikkos G, Busch W, Voulgarelis M, Antoniadou A, et al. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrob Agents Chemother. 2000;44 (12):3264-71.
80. Raad, II, Escalante C, Hachem RY, Hanna HA, Husni R, Afif C, et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer. 2003;98(5):1039-47.
81. Sanz MA, Lopez J, Lahuerta JJ, Rovira M, Batlle M, Perez C, et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother. 2002;50(1):79-88.
82. Tamura K, Matsuoka H, Tsukada J, Masuda M, Ikeda S, Matsuishi E, et al. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study. Am J Hematol. 2002;71(4):248-55.
83. Viscoli C, Cometta A, Kern WV, Bock R, Paesmans M, Crokaert F, et al. Piperacillintazobactam monotherapy in high-risk febrile a nd neutropenic cancer patients. Clin Microbiol Infect. 2006;12(3):212-6.
84. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4): 388-416.
85. Kollef MH. Providing appropriate antimicrobial therapy in the intensive care unit: surveillance vs. de-escalation. Crit Care Med. 2006;34(3):903-5.
86. Morel J, Casoetto J, Jospe R, Aubert G, Terrana R, Dumont A, et al. De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit. Crit Care. 2010;14(6):R225.
87. Ritchie S, Palmer S, Ellis-Pegler R. High-risk febrile neutropenia in Auckland 2003-2004: the influence of the microbiology laboratory on patient treatment and the use of pathogen-specific therapy. Intern Med J. 2007;37(1):26-31.
88. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively DrugResistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial. Clin Infect Dis. 2013;57(3):349-58.
89. Donskey CJ. Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli. Clin Infect Dis. 2006;43(Suppl 2):S62-9.